Pfizer Animal Health has completed its acquisition of Embrex Inc., an international agricultural biotechnology company known for its Inovoject vaccine-delivery systems. The transaction has an aggregate equity purchase price of about $155 million. Embrex, which is now a wholly-owned subsidiary of Pfizer, will continue to be based in Raleigh-Durham, N.C. Embrex common stock is no longer publicly traded and was de-listed from NASDAQ as the close of the market on Jan. 19.
